The DOI matches its Crossref record; 191 of the 191 references it cites were found in a registry or an index.
Gene therapy on the move
Open accessAbstract
The first gene therapy clinical trials were initiated more than two decades ago. In the early days, gene therapy shared the fate of many experimental medicine approaches and was impeded by the occurrence of severe side effects in a few treated patients. The understanding of the molecular and cellular mechanisms leading to treatment‐ and/or vector‐associated setbacks has resulted in the development of highly sophisticated gene transfer tools with improved safety and therapeutic efficacy. Employing these advanced tools, a series of Phase I/II trials were started in the past few years with excellent clinical results and no side effects reported so far. Moreover, highly efficient gene targeting strategies and site‐directed gene editing technologies have been developed and applied clinically. With more than 1900 clinical trials to date, gene therapy has moved from a vision to clinical reality. This review focuses on the application of gene therapy for the correction of inherited diseases, the limitations and drawbacks encountered in some of the early clinical trials and the revival of gene therapy as a powerful treatment option for the correction of monogenic disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310
Viable offspring derived from fetal and adult mammalian cells
Wilmut, I., Schnieke, A. E., McWhir, J., Kind, A. J., & Campbell, K. H. S. (1997) · Nature · doi:10.1038/385810a0 · Cited by 4,969
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Wang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.04.025 · Cited by 3,495
Reprogramming of human somatic cells to pluripotency with defined factors
Park, I.-H., Zhao, R., West, J. A., Yabuuchi, A., Huo, H., Ince, T. A., Lerou, P. H., Lensch, M. W., & Daley, G. Q. (2008) · Nature · doi:10.1038/nature06534 · Cited by 2,436
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
Cavazzana-Calvo, M., Hacein-Bey, S., Basile, G. D. S., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J.-L., et al. (2000) · Science · doi:10.1126/science.288.5466.669 · Cited by 2,167
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
T Lymphocyte-Directed Gene Therapy for ADA − SCID: Initial Trial Results After 4 Years
Blaese, R. M., Culver, K. W., Miller, A. D., Carter, C. S., Fleisher, T., Clerici, M., Shearer, G., Chang, L., Chiang, Y., Tolstoshev, P., et al. (1995) · Science · doi:10.1126/science.270.5235.475 · Cited by 1,550
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512
Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508 · cited 2×
“This was demonstrated in the fi rst clinical trial using a SIN ‐ lentiviral vector for the correction of X ‐ ALD (Cartier et al, 2009).”
Raper, S. E., Chirmule, N., Lee, F. S., Wivel, N. A., Bagg, A., Gao, G.-P., Wilson, J. M., & Batshaw, M. L. (2003) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2003.08.016 · Cited by 1,498
Russell, S. J., Peng, K.-W., & Bell, J. C. (2012) · Nature Biotechnology · doi:10.1038/nbt.2287 · Cited by 1,428
Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells
Ito, K., Hirao, A., Arai, F., Takubo, K., Matsuoka, S., Miyamoto, K., Ohmura, M., Naka, K., Hosokawa, K., Ikeda, Y., et al. (2006) · Nature Medicine · doi:10.1038/nm1388 · Cited by 1,362
Kochenderfer, J. N., Wilson, W. H., Janik, J. E., Dudley, M. E., Stetler-Stevenson, M., Feldman, S. A., Maric, I., Raffeld, M., Nathan, D.-A. N., Lanier, B. J., et al. (2010) · Blood · doi:10.1182/blood-2010-04-281931 · Cited by 1,337
Rosenberg, S. A., Aebersold, P., Cornetta, K., Kasid, A., Morgan, R. A., Moen, R., Karson, E. M., Lotze, M. T., Yang, J. C., Topalian, S. L., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199008303230904 · Cited by 1,318
Brentjens, R. J., Rivière, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S., Borquez-Ojeda, O., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348540 · Cited by 1,286
Howe, S. J., Mansour, M. R., Schwarzwaelder, K., Bartholomae, C., Hubank, M., Kempski, H., Brugman, M. H., Pike-Overzet, K., Chatters, S. J., de Ridder, D., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35798 · Cited by 1,286
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010) · Nature · doi:10.1038/nature09328 · Cited by 1,276
Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy
Biffi, A., Montini, E., Lorioli, L., Cesani, M., Fumagalli, F., Plati, T., Baldoli, C., Martino, S., Calabria, A., Canale, S., et al. (2013) · Science · doi:10.1126/science.1233158 · Cited by 1,180
Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells
Ito, K., Hirao, A., Arai, F., Matsuoka, S., Takubo, K., Hamaguchi, I., Nomiyama, K., Hosokawa, K., Sakurada, K., Nakagata, N., et al. (2004) · Nature · doi:10.1038/nature02989 · Cited by 1,175 · cited 1×
“For example, the engraftment failure in CGD patients may require regulated gene expression of the gp91 phox protein, as inappropriate expression may induce ROS production in HSC with enhanced differentiation and loss of stemness (Ito et al, 2004, 2006; Juntilla et al, 2010).”
Giralt, S., Estey, E., Albitar, M., van Besien, K., Rondón, G., Anderlini, P., O'Brien, S., Khouri, I., Gajewski, J., Mehra, R., et al. (1997) · Blood · doi:10.1182/blood.v89.12.4531 · Cited by 1,138
The Developmental Capacity of Nuclei taken from Intestinal Epithelium Cells of Feeding Tadpoles
Gurdon, J. B. (1962) · Development · doi:10.1242/dev.10.4.622 · Cited by 1,083
The Primary Immunodeficiencies
Rosen, F. S., Cooper, M. D., & Wedgwood, R. J. P. (1984) · New England Journal of Medicine · doi:10.1056/nejm198408023110506 · Cited by 1,077
Kaplitt, M. G., Feigin, A., Tang, C., Fitzsimons, H. L., Mattis, P., Lawlor, P. A., Bland, R. J., Young, D., Strybing, K., Eidelberg, D., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60982-9 · Cited by 1,067
Sustained Correction of X-Linked Severe Combined Immunodeficiency by ex Vivo Gene Therapy
Hacein-Bey-Abina, S., Le Deist, F., Carlier, F., Bouneaud, C., Hue, C., De Villartay, J.-P., Thrasher, A. J., Wulffraat, N., Sorensen, R., Dupuis-Girod, S., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012616 · Cited by 1,058
Ott, M. G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kühlcke, K., Schilz, A., Kunkel, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1393 · Cited by 1,051
Self-citationLentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome
Aiuti, A., Biasco, L., Scaramuzza, S., Ferrua, F., Cicalese, M. P., Baricordi, C., Dionisio, F., Calabria, A., Giannelli, S., Castiello, M. C., et al. (2013) · Science · doi:10.1126/science.1233151 · Cited by 1,025
Self-citationKay, M. A., Manno, C. S., Ragni, M. V., Larson, P. J., Couto, L. B., McClelland, A., Glader, B., Chew, A. J., J Tai, S., Herzog, R. W., et al. (2000) · Nature Genetics · doi:10.1038/73464 · Cited by 1,022
Gene Therapy for Immunodeficiency Due to Adenosine Deaminase Deficiency
Aiuti, A., Cattaneo, F., Galimberti, S., Benninghoff, U., Cassani, B., Callegaro, L., Scaramuzza, S., Andolfi, G., Mirolo, M., Brigida, I., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805817 · Cited by 1,007
Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases
Perez, E. E., Wang, J., Miller, J. C., Jouvenot, Y., Kim, K. A., Liu, O., Wang, N., Lee, G., Bartsevich, V. V., Lee, Y.-L., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1410 · Cited by 999
Retroviral DNA Integration: ASLV, HIV, and MLV Show Distinct Target Site Preferences
Mitchell, R. S., Beitzel, B. F., Schroder, A. R. W., Shinn, P., Chen, H., Berry, C. C., Ecker, J. R., & Bushman, F. D. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020234 · Cited by 976
Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning
Aiuti, A., Slavin, S., Aker, M., Ficara, F., Deola, S., Mortellaro, A., Morecki, S., Andolfi, G., Tabucchi, A., Carlucci, F., et al. (2002) · Science · doi:10.1126/science.1070104 · Cited by 975
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
Hematopoiesis: a human perspective
Doulatov, S., Notta, F., Laurenti, E., & Dick, J. E. (2012) · Cell stem cell · doi:10.1016/j.stem.2012.01.006 · Cited by 895
Lombardo, A., Genovese, P., Beausejour, C. M., Colleoni, S., Lee, Y.-L., Kim, K. A., Ando, D., Urnov, F. D., Galli, C., Gregory, P. D., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1353 · Cited by 845
Human Embryonic Stem Cells Derived by Somatic Cell Nuclear Transfer
Tachibana, M., Amato, P., Sparman, M., Gutierrez, N. M., Tippner-Hedges, R., Ma, H., Kang, E., Fulati, A., Lee, H.-S., Sritanaudomchai, H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.05.006 · Cited by 769
Jessup, M., Greenberg, B., Mancini, D., Cappola, T., Pauly, D. F., Jaski, B., Yaroshinsky, A., Zsebo, K. M., Dittrich, H., & Hajjar, R. J. (2011) · Circulation · doi:10.1161/circulationaha.111.022889 · Cited by 760
Stein, S., Ott, M. G., Schultze-Strasser, S., Jauch, A., Burwinkel, B., Kinner, A., Schmidt, M., Krämer, A., Schwäble, J., Glimm, H., et al. (2010) · Nature Medicine · doi:10.1038/nm.2088 · Cited by 716
Self-citationA novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity
Mussolino, C., Morbitzer, R., Lütge, F., Dannemann, N., Lahaye, T., & Cathomen, T. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr597 · Cited by 714
Montini, E., Cesana, D., Schmidt, M., Sanvito, F., Ponzoni, M., Bartholomae, C., Sergi, L. S., Benedicenti, F., Ambrosi, A., Di Serio, C., et al. (2006) · Nature Biotechnology · doi:10.1038/nbt1216 · Cited by 701
Chronic Granulomatous Disease: The European Experience
van den Berg, J. M., van Koppen, E., Åhlin, A., Belohradsky, B. H., Bernatowska, E., Corbeel, L., Español, T., Fischer, A., Kurenko-Deptuch, M., Mouy, R., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005234 · Cited by 687
LeWitt, P. A., Rezai, A. R., Leehey, M. A., Ojemann, S. G., Flaherty, A. W., Eskandar, E. N., Kostyk, S. K., Thomas, K., Sarkar, A., Siddiqui, M. S., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70039-4 · Cited by 681
Mavilio, F., Pellegrini, G., Ferrari, S., Di Nunzio, F., Di Iorio, E., Recchia, A., Maruggi, G., Ferrari, G., Provasi, E., Bonini, C., et al. (2006) · Nature Medicine · doi:10.1038/nm1504 · Cited by 672
Dystrophin Immunity in Duchenne's Muscular Dystrophy
Mendell, J. R., Campbell, K., Rodino-Klapac, L., Sahenk, Z., Shilling, C., Lewis, S., Bowles, D., Gray, S., Li, C., Galloway, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000228 · Cited by 655
Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells
Scholler, J., Brady, T. L., Binder-Scholl, G., Hwang, W.-T., Plesa, G., Hege, K. M., Vogel, A. N., Kalos, M., Riley, J. L., Deeks, S. G., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003761 · Cited by 652
Wirth, T., Parker, N., & Ylä-Herttuala, S. (2013) · Gene · doi:10.1016/j.gene.2013.03.137 · Cited by 607
Montini, E., Cesana, D., Schmidt, M., Sanvito, F., Bartholomae, C. C., Ranzani, M., Benedicenti, F., Sergi, L. S., Ambrosi, A., Ponzoni, M., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37630 · Cited by 571
Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia
Grossman, M., Raper, S. E., Kozarsky, K., Stein, E. A., Engelhardt, J. F., Muller, D., Lupien, P. J., & Wilson, J. M. (1994) · Nature Genetics · doi:10.1038/ng0494-335 · Cited by 559
McCarty, D. M., Fu, H., Monahan, P. E., Toulson, C. E., Naik, P., & Samulski, R. J. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302134 · Cited by 547
Stem-Cell Gene Therapy for the Wiskott–Aldrich Syndrome
Boztug, K., Schmidt, M., Schwarzer, A., Banerjee, P. P., Díez, I. A., Dewey, R. A., Böhm, M., Nowrouzi, A., Ball, C. R., Glimm, H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003548 · Cited by 532
An unbiased genome-wide analysis of zinc-finger nuclease specificity
Gabriel, R., Lombardo, A., Arens, A., Miller, J. C., Genovese, P., Kaeppel, C., Nowrouzi, A., Bartholomae, C. C., Wang, J., Friedman, G., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1948 · Cited by 526
Gene-engineered T cells for cancer therapy
Kershaw, M. H., Westwood, J. A., & Darcy, P. K. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3565 · Cited by 505
Araki, R., Uda, M., Hoki, Y., Sunayama, M., Nakamura, M., Ando, S., Sugiura, M., Ideno, H., Shimada, A., Nifuji, A., et al. (2013) · Nature · doi:10.1038/nature11807 · Cited by 505
Ylä-Herttuala, S. (2012) · Molecular Therapy · doi:10.1038/mt.2012.194 · Cited by 463
Hematopoietic-Cell Transplantation at 50
Appelbaum, F. R. (2007) · New England Journal of Medicine · doi:10.1056/nejmp078166 · Cited by 461
Effective gene therapy with nonintegrating lentiviral vectors
Yáñez-Muñoz, R. J., Balaggan, K. S., MacNeil, A., Howe, S. J., Schmidt, M., Smith, A. J., Buch, P., MacLaren, R. E., Anderson, P. N., Barker, S. E., et al. (2006) · Nature Medicine · doi:10.1038/nm1365 · Cited by 460
Cideciyan, A. V., Jacobson, S. G., Beltran, W. A., Sumaroka, A., Swider, M., Iwabe, S., Roman, A. J., Olivares, M. B., Schwartz, S. B., Komáromy, A. M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218933110 · Cited by 444
Safe harbours for the integration of new DNA in the human genome
Sadelain, M., Papapetrou, E. P., & Bushman, F. D. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3179 · Cited by 441
SUPRALETHAL WHOLE BODY IRRADIATION AND ISOLOGOUS MARROW TRANSPLANTATION IN MAN*†
Thomas, E. D., Lochte, H. L., Cannon, J. H., Sahler, O. D., & Ferrebee, J. W. (1959) · Journal of Clinical Investigation · doi:10.1172/jci103949 · Cited by 425
Notarangelo, L. D. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.07.053 · Cited by 417
Gaudet, D., Méthot, J., Déry, S., Brisson, D., Essiembre, C., Tremblay, G., Tremblay, K., de Wal, J., Twisk, J., van den Bulk, N., et al. (2013) · Gene Therapy · doi:10.1038/gt.2012.43 · Cited by 404
Modlich, U., Navarro, S., Zychlinski, D., Maetzig, T., Knoess, S., Brugman, M. H., Schambach, A., Charrier, S., Galy, A., Thrasher, A. J., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.179 · Cited by 387
Self-citationReprogrammed viruses as cancer therapeutics: targeted, armed and shielded
Cattaneo, R., Miest, T., Shashkova, E. V., & Barry, M. A. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1927 · Cited by 373
Ex vivo gene transfer and correction for cell-based therapies
Naldini, L. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2985 · Cited by 358
Raper, S. E., Yudkoff, M., Chirmule, N., Gao, G.-P., Nunes, F., Haskal, Z. J., Furth, E. E., Propert, K. J., Robinson, M. B., Magosin, S., et al. (2002) · Human Gene Therapy · doi:10.1089/10430340152712719 · Cited by 354
Segal, A. W., West, I., Wientjes, F., Nugent, J. H. A., Chavan, A. J., Haley, B., Garcia, R. C., Rosen, H., & Scrace, G. (1992) · Biochemical Journal · doi:10.1042/bj2840781 · Cited by 349
Recent Advances in Lentiviral Vector Development and Applications
Mátrai, J., Chuah, M. K., & VandenDriessche, T. (2010) · Molecular Therapy · doi:10.1038/mt.2009.319 · Cited by 347
Malech, H. L., Maples, P. B., Whiting-Theobald, N., Linton, G. F., Sekhsaria, S., Vowells, S. J., Li, F., Miller, J. A., DeCarlo, E., Holland, S. M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.22.12133 · Cited by 336
Site-specific integration and tailoring of cassette design for sustainable gene transfer
Lombardo, A., Cesana, D., Genovese, P., Di Stefano, B., Provasi, E., Colombo, D. F., Neri, M., Magnani, Z., Cantore, A., Lo Riso, P., et al. (2011) · Nature Methods · doi:10.1038/nmeth.1674 · Cited by 331
Long-term follow-up after gene therapy for canavan disease
Leone, P., Shera, D., McPhee, S. W. J., Francis, J. S., Kolodny, E. H., Bilaniuk, L. T., Wang, D.-J., Assadi, M., Goldfarb, O., Goldman, H. W., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003454 · Cited by 307
Sheridan, C. (2011) · Nature Biotechnology · doi:10.1038/nbt.1769 · Cited by 302
Papapetrou, E. P., Lee, G., Malani, N., Setty, M., Riviere, I., Tirunagari, L. M. S., Kadota, K., Roth, S. L., Giardina, P., Viale, A., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1717 · Cited by 299
Zou, J., Mali, P., Huang, X., Dowey, S. N., & Cheng, L. (2011) · Blood · doi:10.1182/blood-2011-02-335554 · Cited by 295
Molineux, G., Pojda, Z., Hampson, I., Lord, B., & Dexter, T. (1990) · Blood · doi:10.1182/blood.v76.10.2153.2153 · Cited by 292
AKT1 and AKT2 maintain hematopoietic stem cell function by regulating reactive oxygen species
Juntilla, M. M., Patil, V. D., Calamito, M., Joshi, R. P., Birnbaum, M. J., & Koretzky, G. A. (2010) · Blood · doi:10.1182/blood-2009-09-241000 · Cited by 284
Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking
Kustikova, O., Fehse, B., Modlich, U., Yang, M., Düllmann, J., Kamino, K., von Neuhoff, N., Schlegelberger, B., Li, Z., & Baum, C. (2005) · Science · doi:10.1126/science.1105063 · Cited by 283
Cell culture assays reveal the importance of retroviral vector design for insertional genotoxicity
Modlich, U., Bohne, J., Schmidt, M., von Kalle, C., Knöss, S., Schambach, A., & Baum, C. (2006) · Blood · doi:10.1182/blood-2005-08-024976 · Cited by 278
Self-citationPhysiological Promoters Reduce the Genotoxic Risk of Integrating Gene Vectors
Zychlinski, D., Schambach, A., Modlich, U., Maetzig, T., Meyer, J., Grassman, E., Mishra, A., & Baum, C. (2008) · Molecular Therapy · doi:10.1038/mt.2008.5 · Cited by 271
Self-citationHot spots of retroviral integration in human CD34+ hematopoietic cells
Cattoglio, C., Facchini, G., Sartori, D., Antonelli, A., Miccio, A., Cassani, B., Schmidt, M., von Kalle, C., Howe, S., Thrasher, A. J., et al. (2007) · Blood · doi:10.1182/blood-2007-01-068759 · Cited by 270
Aiuti, A., Cassani, B., Andolfi, G., Mirolo, M., Biasco, L., Recchia, A., Urbinati, F., Valacca, C., Scaramuzza, S., Aker, M., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31666 · Cited by 252
Neven, B., Leroy, S., Decaluwe, H., Le Deist, F., Picard, C., Moshous, D., Mahlaoui, N., Debré, M., Casanova, J.-L., Dal Cortivo, L., et al. (2009) · Blood · doi:10.1182/blood-2008-09-177923 · Cited by 249
Alphaherpesvirinae and Gammaherpesvirinae glycoprotein L and CMV UL130 originate from chemokines
Malkowska, M., Kokoszynska, K., Dymecka, M., Rychlewski, L., & Wyrwicz, L. S. (2013) · Virology Journal · doi:10.1186/1743-422x-10-1 · Cited by 243
Candotti, F., Shaw, K. L., Muul, L., Carbonaro, D., Sokolic, R., Choi, C., Schurman, S. H., Garabedian, E., Kesserwan, C., Jagadeesh, G. J., et al. (2012) · Blood · doi:10.1182/blood-2012-02-400937 · Cited by 234
Gaspar, H. B., Cooray, S., Gilmour, K. C., Parsley, K. L., Adams, S., Howe, S. J., Al Ghonaium, A., Bayford, J., Brown, L., Davies, E. G., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002715 · Cited by 232
The Lmo2 Oncogene Initiates Leukemia in Mice by Inducing Thymocyte Self-Renewal
McCormack, M. P., Young, L. F., Vasudevan, S., de Graaf, C. A., Codrington, R., Rabbitts, T. H., Jane, S. M., & Curtis, D. J. (2010) · Science · doi:10.1126/science.1182378 · Cited by 231
Therapeutic opportunities for manipulating TReg cells in autoimmunity and cancer
von Boehmer, H., & Daniel, C. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3683 · Cited by 220
Suzuki, N., Yamazaki, S., Yamaguchi, T., Okabe, M., Masaki, H., Takaki, S., Otsu, M., & Nakauchi, H. (2013) · Molecular Therapy · doi:10.1038/mt.2013.71 · Cited by 213
Attenuation of miR-126 Activity Expands HSC In Vivo without Exhaustion
Lechman, E. R., Gentner, B., van Galen, P., Giustacchini, A., Saini, M., Boccalatte, F. E., Hiramatsu, H., Restuccia, U., Bachi, A., Voisin, V., et al. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.09.001 · Cited by 208
Engineering lymphocyte subsets: tools, trials and tribulations
June, C. H., Blazar, B. R., & Riley, J. L. (2009) · Nature Reviews Immunology · doi:10.1038/nri2635 · Cited by 204
Capotondo, A., Milazzo, R., Politi, L. S., Quattrini, A., Palini, A., Plati, T., Merella, S., Nonis, A., di Serio, C., Montini, E., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205858109 · Cited by 200
Notarangelo, L. D., Miao, C. H., & Ochs, H. D. (2008) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3282f30448 · Cited by 196
Resistance of mature T cells to oncogene transformation
Newrzela, S., Cornils, K., Li, Z., Baum, C., Brugman, M. H., Hartmann, M., Meyer, J., Hartmann, S., Hansmann, M.-L., Fehse, B., et al. (2008) · Blood · doi:10.1182/blood-2007-12-128751 · Cited by 195
Lessons learned from the clinical development and market authorization of Glybera
Bryant, L. M., Christopher, D. M., Giles, A. R., Hinderer, C., Rodriguez, J. L., Smith, J. B., Traxler, E. A., Tycko, J., Wojno, A. P., & Wilson, J. M. (2013) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2013.087 · Cited by 189
Recent developments in adeno‐associated virus vector technology
Büning, H., Perabo, L., Coutelle, O., Quadt‐Humme, S., & Hallek, M. (2008) · The Journal of Gene Medicine · doi:10.1002/jgm.1205 · Cited by 187
Self-citationMerten, O.-W., Charrier, S., Laroudie, N., Fauchille, S., Dugué, C., Jenny, C., Audit, M., Zanta-Boussif, M.-A., Chautard, H., Radrizzani, M., et al. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.060 · Cited by 185
Self-citationGammaretroviral Vectors: Biology, Technology and Application
Maetzig, T., Galla, M., Baum, C., & Schambach, A. (2011) · Viruses · doi:10.3390/v3060677 · Cited by 184
Self-citationNanovector delivery of siRNA for cancer therapy
Shen, H., Sun, T., & Ferrari, M. (2012) · Cancer Gene Therapy · doi:10.1038/cgt.2012.22 · Cited by 176
A largely random AAV integration profile after LPLD gene therapy
Kaeppel, C., Beattie, S. G., Fronza, R., van Logtenstein, R., Salmon, F., Schmidt, S., Wolf, S., Nowrouzi, A., Glimm, H., von Kalle, C., et al. (2013) · Nature Medicine · doi:10.1038/nm.3230 · Cited by 176
Stable Gene Transfer to Muscle Using Non-integrating Lentiviral Vectors
Apolonia, L., Waddington, S. N., Fernandes, C., Ward, N. J., Bouma, G., Blundell, M. P., Thrasher, A. J., Collins, M. K., & Philpott, N. J. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300281 · Cited by 174
Biosafety Features of Lentiviral Vectors
Schambach, A., Zychlinski, D., Ehrnstroem, B., & Baum, C. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.229 · Cited by 173
Self-citationDerse, D., Crise, B., Li, Y., Princler, G., Lum, N., Stewart, C., McGrath, C. F., Hughes, S. H., Munroe, D. J., & Wu, X. (2007) · Journal of Virology · doi:10.1128/jvi.02752-06 · Cited by 173
LEDGF Hybrids Efficiently Retarget Lentiviral Integration Into Heterochromatin
Gijsbers, R., Ronen, K., Vets, S., Malani, N., Rijck, J. D., McNeely, M., Bushman, F. D., & Debyser, Z. (2010) · Molecular Therapy · doi:10.1038/mt.2010.36 · Cited by 172
Cattoglio, C., Pellin, D., Rizzi, E., Maruggi, G., Corti, G., Miselli, F., Sartori, D., Guffanti, A., Di Serio, C., Ambrosi, A., et al. (2010) · Blood · doi:10.1182/blood-2010-05-283523 · Cited by 168
RNA Interference and Cancer Therapy
Wang, Z., Rao, D. D., Senzer, N., & Nemunaitis, J. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0604-5 · Cited by 167
Gene Therapy of Chronic Granulomatous Disease: The Engraftment Dilemma
Grez, M., Reichenbach, J., Schwäble, J., Seger, R., Dinauer, M. C., & Thrasher, A. J. (2011) · Molecular Therapy · doi:10.1038/mt.2010.232 · Cited by 162
Self-citationGene Therapy for Heart Failure
Tilemann, L. M., Ishikawa, K., Weber, T., & Hajjar, R. J. (2012) · Circulation Research · doi:10.1161/circresaha.111.252981 · Cited by 160
Advances in targeted genome editing
Perez-Pinera, P., Ousterout, D. G., & Gersbach, C. A. (2012) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2012.06.007 · Cited by 159
Gene therapy for PIDs: Progress, pitfalls and prospects
Mukherjee, S., & Thrasher, A. J. (2013) · Gene · doi:10.1016/j.gene.2013.03.098 · Cited by 158
Anliker, B., Abel, T., Kneissl, S., Hlavatý, J., Caputi, A., Brynza, J., Schneider, I. C., Münch, R. C., Petznek, H., Kontermann, R. E., et al. (2010) · Nature Methods · doi:10.1038/nmeth.1514 · Cited by 146
Gene Therapy for Severe Combined Immunodeficiency
Cavazzana, M., Lagresle‐Peyrou, C., Hacein‐Bey‐Abina, S., & Fischer, A. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.56.090203.104142 · Cited by 146
The Genetic Basis of Chronic Granulomatous Disease
Roos, D. (1994) · Immunological Reviews · doi:10.1111/j.1600-065x.1994.tb00850.x · Cited by 144
Skin Electroporation: Effects on Transgene Expression, DNA Persistence and Local Tissue Environment
Roos, A., Eriksson, F., Timmons, J. A., Gerhardt, J., Nyman, U., Gudmundsdotter, L., Bråve, A., Wahrén, B., & Pisa, P. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007226 · Cited by 144
The Complex and Evolving Story of T cell Activation to AAV Vector-encoded Transgene Products
Mays, L. E., & Wilson, J. M. (2010) · Molecular Therapy · doi:10.1038/mt.2010.250 · Cited by 144
Santilli, G., Almarza, E., Brendel, C., Choi, U., Beilin, C., Blundell, M. P., Haria, S., Parsley, K. L., Kinnon, C., Malech, H. L., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.226 · Cited by 144
Self-citationRailey, M. D., Lokhnygina, Y. V., & Buckley, R. H. (2009) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2009.07.049 · Cited by 143
The Sleeping Beauty transposon system: a non-viral vector for gene therapy
Aronovich, E. L., McIvor, R. S., & Hackett, P. B. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr140 · Cited by 143
Mechanisms of Retroviral Integration and Mutagenesis
Cavazza, A., Moiani, A., & Mavilio, F. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.203 · Cited by 143
Gendicine: The First Commercial Gene Therapy Product; Chinese Translation of Editorial
Wilson, J. M. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.1014 · Cited by 130
Integrase-defective lentiviral vectors: Progress and applications
Banasik, M. B., & McCray, P. B. (2010) · Gene Therapy · doi:10.1038/gt.2009.135 · Cited by 129
Human primary immunodeficiency diseases: a perspective
Fischer, A. (2003) · Nature Immunology · doi:10.1038/ni1023 · Cited by 124
Nowrouzi, A., Penaud‐Budloo, M., Kaeppel, C., Appelt, U., Guiner, C. L., Moullier, P., Kalle, C. V., Snyder, R. O., & Schmidt, M. (2012) · Molecular Therapy · doi:10.1038/mt.2012.47 · Cited by 121
Gene therapy enters the pharma market: The short story of a long journey
Büning, H. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202291 · Cited by 120
Self-citationGene therapy for primary immunodeficiencies: part 1
Cavazzana, M., Fischer, A., Hacein‐Bey‐Abina, S., & Aiuti, A. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.08.008 · Cited by 109
Titman, P., Pink, E., Skucek, E., O'Hanlon, K., Cole, T. J., Gaspar, J., Xu‐Bayford, J., Jones, A., Thrasher, A. J., Davies, E. G., et al. (2008) · Blood · doi:10.1182/blood-2008-04-151332 · Cited by 106
Felice, B., Cattoglio, C., Cittaro, D., Testa, A., Miccio, A., Ferrari, G., Luzi, L., Recchia, A., & Mavilio, F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004571 · Cited by 104
Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy
Hackett, P. B., Largaespada, D. A., Switzer, K. C., & Cooper, L. J. N. (2013) · Translational research · doi:10.1016/j.trsl.2012.12.005 · Cited by 104
Mazzolari, E., Forino, C., Guerci, S., Imberti, L., Lanfranchi, A., Porta, F., & Notarangelo, L. D. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.08.007 · Cited by 102
A review of RGD-functionalized nonviral gene delivery vectors for cancer therapy
Park, J. Y., Singha, K., Son, S., Kim, J., Namgung, R., Yun, C.-O., & Kim, W.-J. (2012) · Cancer Gene Therapy · doi:10.1038/cgt.2012.64 · Cited by 100
Use of Viruses as Carriers of Added Genetic Information
Rogers, S., & Pfuderer, P. (1968) · Nature · doi:10.1038/219749a0 · Cited by 95
New lessons learned from disease modeling with induced pluripotent stem cells
Önder, T. T., & Daley, G. Q. (2012) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2012.05.005 · Cited by 93
Charrier, S., Dupré, L., Scaramuzza, S., Jeanson-Leh, L., Blundell, M. P., Danos, O., Cattaneo, F., Aiuti, A., Eckenberg, R., Thrasher, A. J., et al. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302863 · Cited by 91
Self-citationScaramuzza, S., Biasco, L., Ripamonti, A., Castiello, M. C., Loperfido, M., Draghici, E., Hernández, R. J., Benedicenti, F., Radrizzani, M., Salomoni, M., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.23 · Cited by 90
Marangoni, F., Bosticardo, M., Charrier, S., Draghici, E., Locci, M., Scaramuzza, S., Panaroni, C., Ponzoni, M., Sanvito, F., Doglioni, C., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.31 · Cited by 85
Self-citationGene therapy for primary adaptive immune deficiencies
Fischer, A., Hacein‐Bey‐Abina, S., & Cavazzana, M. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.04.030 · Cited by 82
Gene therapy for retinal disease
McClements, M. E., & MacLaren, R. E. (2013) · Translational Research · doi:10.1016/j.trsl.2012.12.007 · Cited by 80
Cellular immune response to cryptic epitopes during therapeutic gene transfer
Li, C., Goudy, K., Hirsch, M., Asokan, A., Fan, Y., Alexander, J., Sun, J., Monahan, P., Seiber, D., Sidney, J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902269106 · Cited by 79 · cited 1×
“An alternative explanation suggested by mouse studies is the induction of a cytotoxic T ‐ cell response against an epitope produced from the factor IX transgene upon, e.g . usage of an alternative reading frame (Li et al, 2009).”
Gene therapy for primary immunodeficiencies: Part 2
Aiuti, A., Bacchetta, R., Seger, R. A., VILLA, A. M., & Cavazzana, M. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.07.012 · Cited by 79
Gene therapy for chronic granulomatous disease
Barese, C. N., Goebel, W. S., & Dinauer, M. C. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.9.1423 · Cited by 78
Mussolino, C., & Cathomen, T. (2013) · Nature Biotechnology · doi:10.1038/nbt.2527 · Cited by 78
Suerth, J. D., Maetzig, T., Brugman, M. H., Heinz, N., Appelt, J.-U., Kaufmann, K. B., Schmidt, M., Grez, M., Modlich, U., Baum, C., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.309 · Cited by 74
Self-citationMoreno-Carranza, B., Gentsch, M., Stein, S., Schambach, A., Santilli, G., Rudolf, E., Ryser, M., Haria, S., Thrasher, A. J., Baum, C., et al. (2008) · Gene Therapy · doi:10.1038/gt.2008.143 · Cited by 71
Self-citationRevisiting human primary immunodeficiencies
Casanova, J., Fieschi, C., Zhang, S., & Abel, L. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.01971.x · Cited by 68
Kustikova, O. S., Schiedlmeier, B., Brugman, M. H., Stahlhut, M., Bartels, S., Li, Z., & Baum, C. (2009) · Molecular Therapy · doi:10.1038/mt.2009.134 · Cited by 67
Brendel, C., Müller-Kuller, U., Schultze‐Strasser, S., Stein, S., Chen-Wichmann, L., Krattenmacher, A., Kunkel, H., Dillmann, A., Antoniou, M. N., & Grez, M. (2011) · Gene Therapy · doi:10.1038/gt.2011.167 · Cited by 67
Self-citationGene Therapy for Primary Immunodeficiencies
Rivat, C., Santilli, G., Gaspar, H. B., & Thrasher, A. J. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.116 · Cited by 65
Clinical Impact of Suicide Gene Therapy in Allogeneic Hematopoietic Stem Cell Transplantation
Stanghellini, M. T. L., Provasi, E., Bondanza, A., Ciceri, F., Bordignon, C., & Bonini, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.014 · Cited by 64
Recent developments in transposon-mediated gene therapy
Matteo, M. D., Belay, E., Chuah, M., & VandenDriessche, T. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.684875 · Cited by 63
Elsner, M., Terbish, T., Jörns, A., Naujok, O., Wedekind, D., Hedrich, H.-J., & Lenzen, S. (2012) · Molecular Therapy · doi:10.1038/mt.2012.8 · Cited by 62
Progress in Gene Therapy for Chronic Granulomatous Disease
Malech, H. L. (1999) · The Journal of Infectious Diseases · doi:10.1086/513852 · Cited by 57
Gene therapy of primary T cell immunodeficiencies
Fischer, A., Hacein‐Bey‐Abina, S., & Cavazzana, M. (2013) · Gene · doi:10.1016/j.gene.2013.03.092 · Cited by 57
Deichmann, A., Brugman, M. H., Bartholomae, C. C., Schwarzwaelder, K., Verstegen, M. M. A., Howe, S. J., Arens, A., Ott, M., Hoelzer, D. F., Seger, R. A., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.178 · Cited by 57
Self-citationCorrigan‐Curay, J., Cohen‐Haguenauer, O., O’Reilly, M., Ross, S. R., Fan, H., Rosenberg, N. E., Somia, N. V., King, N. M. P., Friedmann, T., Dunbar, C. E., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.93 · Cited by 57
Horowitz, S. D., Bach, F. H., Groshong, T. P., Hong, R., & Yunis, E. J. (1975) · The Lancet · doi:10.1016/s0140-6736(75)90845-4 · Cited by 57
Kastelein, J. J. P., Ross, C. J., & Hayden, M. R. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.063 · Cited by 56
Bacterial vectors for imaging and cancer gene therapy: a review
Cronin, M. A., Stanton, R. M., Francis, K. P., & Tangney, M. (2012) · Cancer Gene Therapy · doi:10.1038/cgt.2012.59 · Cited by 56
Vago, L., Oliveira, G., Bondanza, A., Noviello, M., Soldati, C., Ghio, D., Brigida, I., Greco, R., Stanghellini, M. T. L., Peccatori, J., et al. (2012) · Blood · doi:10.1182/blood-2012-01-405670 · Cited by 53
Loew, R., Meyer, Y., Kuehlcke, K., Gama-Norton, L., Wirth, D., Häuser, H., Stein, S., Grez, M., Thornhill, S. I., Thrasher, A. J., et al. (2009) · Gene Therapy · doi:10.1038/gt.2009.134 · Cited by 51
Self-citationBarde, I., Laurenti, E., Verp, S., Wiznerowicz, M., Offner, S., Viornery, A., Galy, A. H. M., Trumpp, A., & Trono, D. (2011) · Gene Therapy · doi:10.1038/gt.2011.65 · Cited by 50
Self-citationCreating genetic resistance to HIV
Burnett, J., Zaia, J. A., & Rossi, J. J. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.08.013 · Cited by 49
Arens, A., Appelt, J.-U., Bartholomae, C. C., Gabriel, R., Paruzynski, A., Gustafson, D., Cartier, N., Aubourg, P. R., Deichmann, A., Glimm, H., et al. (2012) · Human Gene Therapy Methods · doi:10.1089/hgtb.2011.219 · Cited by 48
Gene Therapy Approaches for Lysosomal Storage Disease: Next-Generation Treatment
Byrne, B. J., Falk, D. J., Clément, N., & Mah, C. S. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.140 · Cited by 48
Gene Therapy for Chronic Granulomatous Disease
Goebel, W. S., & Dinauer, M. C. (2003) · Acta Haematologica · doi:10.1159/000072457 · Cited by 46
Hu, B., Dai, B., & Wang, P. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.08.012 · Cited by 45
Stewart, H. J., Fong-Wong, L., Strickland, I. T., Chipchase, D., Kelleher, M., Stevenson, L., Thoree, V., McCarthy, J., Ralph, G. S., Mitrophanous, K. A., et al. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.142 · Cited by 45
Carbonaro, D. A., Jin, X., Wang, X., Yu, X., Rozengurt, N., Kaufman, M. L., Wang, X., Gjertson, D. W., Zhou, Y., Blackburn, M. R., et al. (2012) · Blood · doi:10.1182/blood-2012-02-408591 · Cited by 44
Frecha, C. A., Costa, C., Négre, D., Amirache, F., Trono, D., Río, P., Bueren, J. A., Cosset, F., & Verhoeyen, E. (2011) · Blood · doi:10.1182/blood-2011-04-346619 · Cited by 43
Solving the Problem of γ-Retroviral Vectors Containing Long Terminal Repeats
Persons, D. A., & Baum, C. (2011) · Molecular Therapy · doi:10.1038/mt.2010.305 · Cited by 42
An update on gene therapy in China.
Shi, J., & Zheng, D. (2009) · PubMed · Cited by 42
Current progress on gene therapy for primary immunodeficiencies
Zhang, L., Thrasher, A. J., & Gaspar, H. B. (2013) · Gene Therapy · doi:10.1038/gt.2013.21 · Cited by 40
Kaufmann, K. B., Brendel, C., Suerth, J. D., Müller-Kuller, U., Chen-Wichmann, L., Schwäble, J., Pahujani, S., Kunkel, H., Schambach, A., Baum, C., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.249 · Cited by 33
Self-citationThe innovative evolution of cancer gene and cellular therapies
Lam, P., Khan, G. N., Stripecke, R., Hui, K. M., Kasahara, N., Peng, K.-W., & Guinn, B. (2013) · Cancer Gene Therapy · doi:10.1038/cgt.2012.93 · Cited by 28
Brendel, C., Haenseler, W., Wohlgensinger, V., Bianchi, M., Tokmak, S., Chen-Wichmann, L., Kuzmenko, E. S., Cesarovic, N., Nicholls, F., Reichenbach, J., et al. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.157 · Cited by 27
Self-citationBrugman, M. H., Suerth, J. D., Rothe, M., Suerbaum, S., Schambach, A., Modlich, U., Kustikova, O. S., & Baum, C. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.175 · Cited by 23
Self-citationTheSleeping Beautytransposon system for clinical applications
Swierczek, M., Izsvák, Z., & Ivics, Z. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.642358 · Cited by 23
Creation of a cardiotropic adeno-associated virus: the story of viral directed evolution
Yang, L., & Xiao, X. (2013) · Virology Journal · doi:10.1186/1743-422x-10-50 · Cited by 22
Ebina, H., Kanemura, Y., Suzuki, Y., Urata, K., Misawa, N., & Koyanagi, Y. (2012) · Virology · doi:10.1016/j.virol.2012.02.004 · Cited by 22
A minimal c-fes cassette directs myeloid-specific expression in transgenic mice
Heydemann, A., Warming, S., Clendenin, C., Sigrist, K. S., Hjorth, J. P., & Simon, M. C. (2000) · Blood · doi:10.1182/blood.v96.9.3040 · Cited by 20
Muscle CARs and TcRs: turbo-charged technologies for the (T cell) masses
Kalos, M. D. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1173-5 · Cited by 20
Cell type specific gene delivery by lentiviral vectors
Zhou, Q., & Buchholz, C. J. (2013) · OncoImmunology · doi:10.4161/onci.22566 · Cited by 18
Will T-cell therapy for cancer ever be a standard of care?
Brenner, M. K. (2012) · Cancer Gene Therapy · doi:10.1038/cgt.2012.74 · Cited by 18
Homologous recombination in human iPS and ES cells for use in gene correction therapy
Nakayama, M. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.01.006 · Cited by 15
Genetic correction of X-linked chronic granulomatous disease with novel foamy virus vectors
Chatziandreou, I., Siapati, E. K., & Vassilopoulos, G. (2011) · Experimental Hematology · doi:10.1016/j.exphem.2011.03.003 · Cited by 14
Cardiac Gene Therapy: From Concept to Reality
Kratlian, R. G., & Hajjar, R. J. (2011) · Current Heart Failure Reports · doi:10.1007/s11897-011-0077-1 · Cited by 14
“Special Exemptions”: Should They Be Put on Trial?
Gaspar, H. B., Swift, S. M., & Thrasher, A. J. (2013) · Molecular Therapy · doi:10.1038/mt.2013.1 · Cited by 11
Cited by
RNA-based therapeutics: an overview and prospectus
Zhu, Y., Zhu, L., Wang, X., & Jin, H. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05075-2 · Cited by 623
Therapeutic approaches for cardiac regeneration and repair
Hashimoto, H., Olson, E. N., & Bassel-Duby, R. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0036-6 · Cited by 415
Teratozoospermia: spotlight on the main genetic actors in the human
Coutton, C., Escoffier, J., Martinez, G., Arnoult, C., & Ray, P. F. (2015) · Human Reproduction Update · doi:10.1093/humupd/dmv020 · Cited by 352
Gene Therapy Leaves a Vicious Cycle
Goswami, R., Subramanian, G., Silayeva, L., Newkirk, I., Doctor, D., Chawla, K., Chattopadhyay, S., Chandra, D., Chilukuri, N., & Betapudi, V. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00297 · Cited by 347
The approved gene therapy drugs worldwide: from 1998 to 2019
Ma, C.-C., Wang, Z.-L., Xu, T., He, Z.-Y., & Wei, Y.-Q. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.107502 · Cited by 310
Metadata
- Authors
- Kaufmann, K. B., Büning, H., Galy, A., Schambach, A., & Grez, M.
- Venue
- EMBO Molecular Medicine
- Published
- 2013-09-17
- Volume
- 5
- Issue
- 11
- Pages
- 1642-1661
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2129583958
- Cited by
- 276
- References
- 191
- FWCI
- 13.76
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.